The scientist’s investigation covers issues in Psychiatry, Psychosis, Schizophrenia, Neuroscience and Prodrome. Keith A. Hawkins combines subjects such as Internal medicine, Randomized controlled trial and Clinical trial with his study of Psychiatry. His Psychosis study incorporates themes from Clinical psychology, Audiology, Severity of illness and Neuropsychology.
He has researched Clinical psychology in several fields, including Meta-analysis, Cognition and Family history. His Schizophrenia research focuses on Neurocognitive and how it connects with Cognitive skill, Developmental psychology, Episodic memory and Apolipoprotein E. His work deals with themes such as Observational study, Disease etiology and Healthy subjects, which intersect with Neuroscience.
His scientific interests lie mostly in Psychiatry, Cognition, Schizophrenia, Clinical psychology and Psychosis. Many of his research projects under Psychiatry are closely connected to Population with Population, tying the diverse disciplines of science together. Keith A. Hawkins combines subjects such as Test, Gerontology and Audiology with his study of Cognition.
When carried out as part of a general Schizophrenia research project, his work on Schizophrenic Psychology and Risperidone is frequently linked to work in Context, therefore connecting diverse disciplines of study. His Clinical psychology study combines topics in areas such as Developmental psychology and Cognitive test. The concepts of his Psychosis study are interwoven with issues in Severity of illness, Cognitive disorder and Atypical antipsychotic.
Cognition, Audiology, Depression, Clinical Dementia Rating and Cohort study are his primary areas of study. His research integrates issues of Adverse effect and Randomized controlled trial in his study of Cognition. Keith A. Hawkins undertakes interdisciplinary study in the fields of Audiology and Artificial neural network through his research.
His Depression research is multidisciplinary, incorporating perspectives in Surgery, Delirium, Rating scale, Transcranial Doppler and Risk factor. His Delirium course of study focuses on Dementia and Physiology, Neuroscience, Apolipoprotein E, Middle age and Neuropsychological assessment. His Clinical Dementia Rating study combines topics from a wide range of disciplines, such as Wechsler Memory Scale, Verbal learning and Cognitive decline.
His main research concerns Hyposmia, Depression, Dementia, Clinical Dementia Rating and Transcranial Doppler. His Hyposmia research spans across into subjects like Montreal Cognitive Assessment, REM sleep behavior disorder, Internal medicine, Dementia with Lewy bodies and Parkinson's disease. His biological study spans a wide range of topics, including Judgment of Line Orientation, Neuropsychology and Cohort.
Keith A. Hawkins has included themes like Odds ratio, Surgery, Cohort study, Delirium and Risk factor in his Depression study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf.
Progress in Neurobiology (2011)
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.
Thomas H. McGlashan;Robert B. Zipursky;Diana Perkins;Jean Addington.
American Journal of Psychiatry (2006)
Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations.
Ralph E. Hoffman;Keith A. Hawkins;Ralitza Gueorguieva;Nash N. Boutros.
Archives of General Psychiatry (2003)
Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis
Larry J. Seidman;Anthony J. Giuliano;Eric C. Meyer;Jean Addington.
Archives of General Psychiatry (2010)
The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis
Nick M. Wisdom;Jennifer L. Callahan;Jennifer L. Callahan;Keith A. Hawkins.
Neurobiology of Aging (2011)
Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample
Ralph E. Hoffman;Ralitza Gueorguieva;Keith A. Hawkins;Maxine Varanko.
Biological Psychiatry (2005)
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
Ju-Hee Kang;Ju-Hee Kang;David J. Irwin;Alice S. Chen-Plotkin;Andrew Siderowf.
JAMA Neurology (2013)
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.
T. H. McGlashan;R. B. Zipursky;D. Perkins;J. Addington.
Schizophrenia Research (2003)
Endophenotypes in schizophrenia: a selective review.
Allyssa J. Allen;Mélina E. Griss;Bradley S. Folley;Keith A. Hawkins.
Schizophrenia Research (2009)
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome
Scott W Woods;Alan Breier;Robert B Zipursky;Diana O Perkins.
Biological Psychiatry (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Yale University
Yale University
Yale University
University of Calgary
Yale University
University of North Carolina at Chapel Hill
Indiana University
University of New Mexico
University of Toronto
University of Pennsylvania
University of Haifa
Intel (United States)
University of Auckland
Karlsruhe Institute of Technology
Harbin Institute of Technology
National Institutes of Health
Anglia Ruskin University
Max Planck Society
University of Oslo
University of Bordeaux
National Taiwan Ocean University
University of Würzburg
Pennsylvania State University
Philips (Finland)
Harvard University
University of Southern Denmark